Trial Profile
An Open-Label, Parallel Group, Controlled Study in Healthy Subjects to Characterize Biological Responses to Immunological Challenges and to Measure the Effect of Marketed Anti-Inflammatory Agents on Those Responses
Status:
Completed
Phase of Trial:
Phase 0
Latest Information Update: 09 May 2019
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary) ; Methylprednisolone (Primary)
- Indications Endotoxinaemia
- Focus Pharmacodynamics
- 10 Oct 2014 There is discrepancy in number of subjects, however reported 51 as they might have taken 30 who meets inclusion and exclusion criteria out of 51.
- 10 Oct 2014 New trial record